



Final Appraisal Recommendation

Advice No: 2712 – December 2012

Eplerenone (Inspra®) 25 mg and 50 mg film-coated tablets

Submission by Pfizer Ltd

Recommendation of the All Wales Medicines Strategy Group

Eplerenone (Inspra®) is recommended as an option for use within NHS Wales in addition to standard optimal therapy, to reduce the risk of cardiovascular mortality and morbidity in adult patients with New York Heart Association (NYHA) class II (chronic) heart failure and left ventricular systolic dysfunction (LVEF \leq 30%).

Additional note:

- AWMSG is of the opinion that eplerenone (Inspra®) may be appropriate for prescribing by all prescribers within NHS Wales for the above recommendation.

In reaching the above recommendation AWMSG has taken account of the appraisal documentation prepared by the AWMSG Secretariat (reference number 763), which includes the AWMSG Secretariat Assessment Report (ASAR), the Preliminary Appraisal Recommendation (PAR) and the applicant company's response to the PAR, clinical expert opinion (where available), the views of patients/patient carers (where available) and the lay member perspective.

The All Wales Therapeutics and Toxicology Centre (AWTTC) reviewed this appraisal recommendation in November 2022. No new evidence was identified that is likely to significantly affect the current recommendation. Therefore, this recommendation has been transferred to AWMSG's static list of medicine recommendations.

Statement of use: No part of this recommendation may be reproduced without the whole recommendation being quoted in full and cited as:

All Wales Medicines Strategy Group Final Appraisal Recommendation –
2712: Eplerenone (Inspra®) 25 mg and 50 mg film-coated tablets.
December 2012.